Rapport Therapeutics (NASDAQ:RAPP) CFO Purchases $99,990.00 in Stock

Rapport Therapeutics (NASDAQ:RAPP) CFO Troy A. Ignelzi acquired 9,900 shares of the company’s stock in a transaction dated Wednesday, March 12th. The stock was purchased at an average cost of $10.10 per share, for a total transaction of $99,990.00. Following the purchase, the chief financial officer now directly owns 9,900 shares in the company, valued at approximately $99,990. This represents a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which is available through this link.

Rapport Therapeutics Stock Performance

Shares of NASDAQ RAPP traded up $0.01 during mid-day trading on Thursday, reaching $10.02. The company had a trading volume of 227,750 shares, compared to its average volume of 166,430. Rapport Therapeutics has a 1-year low of $6.43 and a 1-year high of $29.74. The company has a 50-day moving average price of $13.88 and a two-hundred day moving average price of $18.88.

Institutional Trading of Rapport Therapeutics

A number of institutional investors have recently bought and sold shares of RAPP. BNP Paribas Financial Markets acquired a new stake in shares of Rapport Therapeutics in the third quarter worth about $34,000. KLP Kapitalforvaltning AS bought a new position in Rapport Therapeutics during the 4th quarter worth about $34,000. Deutsche Bank AG bought a new position in shares of Rapport Therapeutics in the 4th quarter valued at about $41,000. New York State Common Retirement Fund acquired a new stake in Rapport Therapeutics in the 4th quarter valued at about $62,000. Finally, Virtus ETF Advisers LLC acquired a new stake in Rapport Therapeutics during the fourth quarter worth approximately $66,000.

About Rapport Therapeutics

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.